Tandem Diabetes (TNDM) Tops Q4 EPS by 7c, Beats on Revenues; Offers FY18 Revenue Outlook Above Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Tandem Diabetes Care (TNDM) PT Raised to $4 at Stifel
March 5, 2018 7:16 AM ESTStifel raised its price target on Tandem Diabetes Care (NASDAQ: TNDM) to $4.00 (from $3.00) while maintaining a Hold rating following the company's 4Q. sales were at the high end of the companys January 9th pre-announced $39-$40M range, and the company exited 2017 with record... More
Tandem Diabetes Care (TNDM) PT Doubled to $5 at Cowen; Outlook Improved Significantly
February 27, 2018 9:39 AM ESTCowen raised its price target on Tandem Diabetes Care (NASDAQ: TNDM) to $5.00 (from $2.50) while maintaining a Market Perform rating.
Analyst Doug Schenkel commented, "The outlook has significantly improved. For the first time since we began covering TNDM, we believe there is a... More
Oppenheimer Starts Tandem (TNDM) at Outperform
February 27, 2018 8:14 AM ESTOppenheimer initiates coverage on Tandem (NASDAQ: TNDM) with a Outperform rating and a price target of $5.50.
For an analyst ratings summary and ratings history on Tandem click here. For more ratings news on Tandem click here.
Shares of Tandem closed at $3.10 yesterday.
... More